Clinical Trial Detail

NCT ID NCT02061761
Title Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Bristol-Myers Squibb
Indications

diffuse large B-cell lymphoma

Hodgkin's lymphoma

non-Hodgkin lymphoma

multiple myeloma

chronic lymphocytic leukemia

Therapies

Nivolumab + Relatlimab

Relatlimab

Age Groups: adult

No variant requirements are available.